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Key Clinical Message
Primary immunodeficiency disorders are rarely diagnosed in adults but must be
considered in the differential diagnosis of combined recurrent infections and
autoimmune disease. We describe a patient with CTLA-4 haploinsufficiency
and an abnormal regulatory T-cell phenotype. Unusually, infections were more
severe than autoimmunity, illustrating therapeutic challenges in disease course.
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Introduction
We report the identification of a fatal heterozygous muta-
tion in CTLA-4. The mutation was predicted to decrease
protein stability resulting in haploinsufficiency and
decreased CTLA-4 expression in CD4+Foxp3+ T cells.
The patient suffered from autoimmunity (Evan’s syn-
drome), lymphoproliferation (diarrhea with intestinal
inflammation), and immunocompromise (severe infec-
tions).
Heterozygous cytotoxic T lymphocyte antigen-4
(CTLA-4) mutations have recently been recognized to
cause diverse clinical phenotypes [1, 2] with unpredictable
responses to a wide range of therapies, ranging from
immunosuppressants to bone marrow transplantation [3].
We present a patient with a novel mutation and a fatal
outcome.
Case Report
In 2013, a 45-year-old Portuguese man (born to noncon-
sanguineous parents) was admitted for sepsis. An elective
total hip replacement 6 months before had been followed
by recurrent urosepsis. Clinical features and laboratory
investigations are presented in Table 1. Evans syndrome
had been diagnosed at 9 years, at which time lifelong
steroid therapy was started. He had multiple episodes of
otitis during childhood. From young adulthood, he com-
plained of intermittent diarrhea. Previous upper and
lower gastrointestinal endoscopic studies failed to reveal
any abnormality except for a mild ileal inflammatory
infiltrate on histology. He had been hospitalized three
separate times over the past 10 years for episodes of
hemolysis and severe thrombocytopenia, pneumonia, and
lower limb cellulitis. There was no relevant family history.
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Clinical examination was unremarkable apart from pro-
portionate short stature (150.0 cm), hepatosplenomegaly
but no lymphadenopathy. He had a normal hemoglobin
and platelet count. Despite a normal total leukocyte
count, there was lymphopenia. Flow cytometric analysis
performed while patient was under prednisolone 5 mg/day
showed a marked reduction in CD8+ T cells and CD19+
B cells. Total IgG and IgA were low, IgE and IgD were
undetectable, and IgM was normal. Antidiphtheria Ab:
0.44 UI/mL (protection titer >1.0 UI/mL); peripheral
blood mononuclear cell proliferation to PHA, PPD, and
Candida were slightly reduced. He also had prostatic
hypertrophy, a urethral stricture, and a trabeculated
bladder. He was discharged on intravenous immunoglob-
ulin (IVIG) (0.6 g/kg body weight every 3 to 4 weeks)
and maintained on prednisolone 5 mg/day, prophylac-
tic nitrofurantoin 100 mg/day, and tamsulosin 0.4 mg/
day.
Table 1. Patient’s features, investigation results, and immunological studies up to the diagnosis.
Clinical features—age (y) and treatment from diagnosis Immunoglobulins and lymphocyte counts
9 y and childhood
• Evans syndrome
• Multiple episodes otitis
25–42 y
• Episodic diarrhea
• Multiple hospital admissions:
a hemolysis + thrombocytopenia
b pneumonia, lower limb cellulitis
• Cholecystitis
• Bilateral osteonecrosis of femoral head and condyles 43 y
• Elective right hip replacement. Postoperative: recurrent urosepsis caused
by Enteroccocus faecalis, Klebsiella pneumoniae and Pseudomonas aeruginosa.
44 y—October 2013
• Facial vitiligo, hepatosplenomegaly
• Hemoglobin 12.5 g/L; leukocytes: 8700/lL; platelets 28000/lL
• Benign prostatic hypertrophy; urethral stricture; trabeculated bladder
• Duodenal, ileal and bladder biopsy: inflammatory infiltrate (not characterized)
• Negative: direct Coombs, ANA, EBV DNA, CMV DNA, hepatitis B, C,
HIV, proteinuria, urinary Ig loss
• Antiplatelet Ab positive
44 y – Pre-IVIG – October 2013
• Immunoglobulins (g/L) (normal range)
IgG 3.4 (6.9–14.0); IgA 0.4 (0.88–4.1); IgM 0.77 (0.34–2.1);
IgE <0.4 (<10); IgD <0.01 (0.01–1.5)
• Lymphocytes: 680/lL (normal >1000/lL)
Subpopulations, [%; total cells/lL (normal range)]:
T cells:
CD3+ 86% (55–84); 608 (690–2540)
CD4+ 75% (31–60); 528 (410–1590)
CD8+ 11% (13–41); 80 (190–1140)
B cells: CD19+ 2% (6–25); 17 (90–660)
NK cells: CD3/CD16+56+ 11% (5–27); 78 (90–590)
• Maturation and activation markers [%; total cells/lL
(normal range)]:
CD4+T cells:
CD45RA+ 13% (3–59); 24 (27–833)
CD45RO+ 70% (15–69); 130 (167–670)
CD8+T cells:
CD45RA+ 50% (6–84); 38 (19–508)
CD45RO+ 66% (4–49); 51 (15–275)
B-cell subpopulations gated out of CD19+:
Naive CD27 IgD+ IgM+ 64% (42–82); 4
Memory CD27+ 30%; 2
Memory CD27+ IgD+ Marginal zone 24%; 6
Memory switched CD27+ IgD 1
Transitional CD38+ IgMhi 0.1
ANA, antinuclear antibody; IVIG, intravenous immunoglobulin substitution; MP, methyl–prednisolone (500 mg/day 9 3); Ab, antibody; values out-
side the normal range are given in bold.
Figure 1. (A) Diagnosis of the CTLA-4 mutation. Broad genetic screening using a custom panel of many immune-related genes using an ion
proton next-generation sequencer, followed by Sanger sequencing, was performed at the Laboratory of Clinical and Infectious Diseases of the
National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. This figure shows Sanger sequencing confirmation of the mutation. The
top tracing is from a control and the bottom tracing from the patient. CTLA-4 sequencing was performed after amplification of the four exons.
Shown is the translated protein of the gene containing 4 domains, indicated above the exons. In the patient, two peaks representing the wild-
type allele (containing A, like in the control) and the mutated allele (containing the mutant G) are shown. This mutation caused a substitution of
cysteine (Cys) for tyrosine (Tyr) in the ligand-binding domain (exon 2). (B) CTLA-4 expression within regulatory T cells. Methods for surface
staining of peripheral blood mononuclear cells (PBMCs) using validated antibodies and intracellular staining with anti-FoxP3 and CD152
antibodies, sample acquisition, and analysis were previously described. Flow cytometric analysis of FoxP3, CD25, and CTLA4 expressions within
gated CD4+ T peripheral blood cells (defined as CD4+CD3+ cells) from the patient and a healthy control. Also depicted in histogram overlay is the
expression of CTLA4 and corresponding isotype control within CD4+CD25+CD127hi cells. For direct comparison of CTLA4 expression within
CD4+CD25+CD127hi cells from patient and healthy control, a histogram overlay with the corresponding values of CTLA4 geometric mean is
shown in below panel. Foxp3 and CTLA-4 stainings are intracellular and performed in the absence of stimulation.
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Broad genetic panel screening followed by Sanger con-
firmation identified the heterozygous CTLA-4 mutation
c.380A>G, p.Tyr127Cys (Figure 1A). This mutation was
not found in ESP6500 [4], dbSNP [5], 1000G [6], or
ExAC [7] databases. Computational predictors (SIFT [8],
Polyphen-2 [9], MutPred [10], PredictSNP [11], PRO-
VEAN [12], PON-P2 [13], Mutation Taster [14],
MetaSNP [15], I-Mutant Suite [16], and IStable [17]) of
the effect of missense mutations assessed Tyr127Cys to be
deleterious, damaging, pathogenic, and likely disease caus-
ing or to decrease protein stability (Table 2). No familial
segregation analysis could be performed as the patient0s
first-degree relatives (reportedly healthy) refused genetic
testing, and the patient had no progeny. Further
immunophenotyping disclosed excess in the frequency of
mature T cells, contrasting with absence of memory B
lymphocytes. Within the CD4+ T lymphocytes, the fre-
quency of the Foxp3+ regulatory T-cell (Treg) population
was slightly reduced compared to a healthy control.
CD4+Foxp3+ T cells additionally displayed reduced levels
of CD25 and CTLA-4 expressions (Figure 1B).
Outcome and Follow-up
For the next 3 years, the patient remained free of infec-
tion on IVIG replacement (0.6–0.8 g/kg) every 3–4 weeks,
with a median IgG concentration of approximately 6 g/L.
In October 2016, he underwent a transurethral resection
of the prostate and soon afterward developed diarrhea
and significant weight loss. He was again admitted to our
hospital, but after extensive investigation, no infectious or
immune-mediated cause could be found. There was an
excellent response to a short course of a higher dose of
oral prednisolone (30 mg/day, tapered over the next
2 months to 5 mg/day). In February 2017, he was admit-
ted to his local hospital with left-sided epididymo-orchitis
and rapidly died from hospital-acquired pneumonia.
Discussion
We describe a novel CTLA-4 mutation causing a quanti-
tative defect in protein expression associated with an
altered phenotype of regulatory T cells. Tyr127Cys affects
a highly conserved amino acid located in the ligand-bind-
ing domain, close to the MYPPPY CD80- and CD86-
binding motif (amino acid positions 133–139), which is
considered critical for protein function [18].
Inhibition of CTLA-4 has recently become important
in the immunotherapy of cancer, a side effect of which is
multisystem autoimmune disease [19]. In health, func-
tional Tregs control autoimmunity, using CD25 and con-
stitutive CTLA-4 expression for fully competent effector
function [20]. In our patient, Treg frequency was reduced
and we surmise that the Treg function was hampered, as
a consequence of the significant reduction in CD25 and
CTLA-4 expressions within this subset. The severe reduc-
tion in memory B cells is consistent with his humoral
immunodeficiency. Of note, Enteroccocus infection has
been described in patients with Treg mutations [21]. The
low-dose steroid regimen may have affected in vitro pro-
liferation, but the overall changes are consistent with a
defect in T- and B-cell regulation due to CTLA-4 hap-
loinsufficiency with autoimmunity (Evan’s syndrome),
lymphoproliferation (diarrhea with intestinal inflamma-
tion), and immunocompromise (severe infections).
CTLA-4 heterozygosity poses formidable diagnostic and
treatment challenges. Abatacept (a fusion protein of the
extracellular domain of CTLA-4 and human IgG1) was
not considered in our patient as immunodeficiency,
rather than autoimmunity, predominated in the course of
his disease. Similarly, bone marrow transplantation
(BMT), which has been performed primarily in those
with severe refractory autoimmune disease or chronic
life-threatening infections [3], did not seem appropriate
in our patient. In hindsight, even though our patient sur-
vived to adulthood, in view of previous life-threatening
infections, he may have benefited from allogeneic BMT.
We went as far as donor HLA assessment, but there was
no familial match, and in any case, he was not accepted
into a recipient list.
This patient was heterozygous for a novel CTLA-4 mis-
sense mutation, which was predicted to be damaging and
to affect protein stability and/or function. A causal link
between CTLA-4 heterozygosity, immunodeficiency, and
autoimmune disease is strongly suggested but not proven.
The mutation found, its predicted damage, and recurrent
Table 2. Computational predictor results for the substitution of a tyr-
osine for a cysteine at amino acid position 127 in human CTLA4.
ESP6500 Not present
dbSNP Not present
1000G Not present
ExAC Not present
SIFT Damaging (score 0)
Polyphen-2 Probably damaging (score 1)
MutPred Deleterious (0.862 probability)
PredictSNP Deleterious
PROVEAN Deleterious (score 8.456)
PON-P2 Pathogenic (0.888 probability)
Mutation Taster Disease causing
MetaSNP Disease causing (score 0.785)
I-Mutant Suite Large decrease in protein stability
(DDG = 1.18 kcal/mol)
IStable Decrease in protein stability (PDB 1I8L,
DDG = 1.5299; PDB 3OSK,
DDG = 1.18 kcal/mol)
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life-threatening infections account for the seriousness and
uniqueness of his condition. Particularly in those patients
in whom the severity of immunodeficiency surpasses the
autoimmunity, making the correct therapeutic choices
remains an ongoing challenge.
Ethical Approval
The patient signed informed consent for genetic testing
and case publication.
Acknowledgment
The authors would like to thank Joie Davis for informed
consent.
Conflict of Interest
The authors have declared no conflicts of interest.
Authorship
All authors: participated in manuscript writing (mw);
MM-F: overall responsibility for mw and patient care
(pc); AA, FL, AVT, AL: pc, and CM: cytometry; IC: com-
putational predictions; APH, SMH, and GU: genetic test-
ing, computational predictions, and cytometry.
References
1. Kuehn, H. S., W. Ouyang, B. Lo, E. K. Deenick, J. E.
Niemela, D. T. Avery, et al. 2014. Immune dysregulation
in human subjects with heterozygous germline mutations
in CTLA4. Science 345:1623–1627.
2. Schubert, D., C. Bode, R. Kenefeck, T. Z. Hou, J. B. Wing,
A. Kennedy, et al. 2014. Autosomal dominant immune
dysregulation syndrome in humans with CTLA4
mutations. Nat. Med. 20:1410–1416.
3. Slatter, M. A., K. R. Engelhardt, L. M. Burroughs, P. D.
Arkwright, Z. Nademi, S. Skoda-Smith, et al. 2016.
Hematopoietic stem cell transplantation for CTLA4
deficiency. J. Allergy Clin. Immunol. 138:615–619e1.
4. ESP6500 ref: http://evs.gs.washington.edu/EVS
5. Sherry, S. T., M. H. Ward, M. Kholodov, J. Baker, L. Phan,
E. M. Smigielski, et al. 2001. dbSNP: the NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311.
6. Genomes Project Consortium, A. Auton, L. D. Brooks, R.
M. Durbin, E. P. Garrison, H. M. Kang, et al. 2015. A
global reference for human genetic variation. Nature
526:68–74..E4.
7. ExAC ref: Exome Aggregation Consortium. http://exac.b
roadinstitute.org
8. Kumar, P., S. Henikoff, and P. C. Ng. 2009. Predicting the
effects of coding non-synonymous variants on protein
function using the SIFT algorithm. Nat. Protoc. 4:1073–1081.
9. Adzhubei, I. A., S. Schmidt, L. Peshkin, V. E. Ramensky,
A. Gerasimova, P. Bork, et al. 2010. A method and server
for predicting damaging missense mutations. Nat. Methods
7:248–249.
10. Li, B., V. G. Krishnan, M. E. Mort, F. Xin, K. K. Kamati,
D. N. Cooper, et al. 2009. Automated inference of
molecular mechanisms of disease from amino acid
substitutions. Bioinformatics 25:2744–2750.
11. Bendl, J., J. Stourac, O. Salanda, A. Pavelka, E. D. Wieben,
J. Zendulka, et al. 2014. PredictSNP: robust and accurate
consensus classifier for prediction of disease-related
mutations. PLoS Comput. Biol. 10:e1003440.
12. Choi, Y., and A. P. Chan. 2015. PROVEAN web server: a
tool to predict the functional effect of amino acid
substitutions and indels. Bioinformatics 31:2745–2747.
13. Niroula, A., S. Urolagin, and M. Vihinen. 2015. PON-P2:
prediction method for fast and reliable identification of
harmful variants. PLoS ONE 10:e0117380.
14. Schwarz, J. M., D. N. Cooper, M. Schuelke, and D.
Seelow. 2014. MutationTaster2: mutation prediction for
the deep-sequencing age. Nat. Methods 11:361–362.
15. Capriotti, E., R. B. Altman, and Y. Bromberg. 2013.
Collective judgment predicts disease-associated single
nucleotide variants. BMC Genom. 14(Suppl. 3):S2.
16. Capriotti, E., P. Fariselli, and R. Casadio. 2005. I-
Mutant2.0: predicting stability changes upon mutation
from the protein sequence or structure. Nucleic Acids Res.
33:W306–W310.
17. Chen, C. W., J. Lin, and Y. W. Chu. 2013. iStable: off-the-
shelf predictor integration for predicting protein stability
changes. BMC Bioinformatics 14(Suppl. 2):S5.
18. Schwartz, J. C., X. Zhang, A. A. Fedorov, S. G. Nathenson,
and S. C. Almo. 2001. Structural basis for co-stimulation
by the human CTLA-4/B7-2 complex. Nature 410:604–608.
19. Peterson, J. J., and S. K. Steele-Moses. 2016. Update on
new therapies with immune checkpoint inhibitors. Clin. J.
Oncol. Nurs. 20:405–410.
20. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono.
2008. Regulatory T cells and immune tolerance. Cell
133:775–787.
21. Wildin, R. S., S. Smyk-Pearson, and A. H. Filipovich.
2002. Clinical and molecular features of immune
dysregulation, polyendocrinopathy, and X linked
inheritance (IPEX) a syndrome. J. Med. Genet. 39:537–
545.
ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 5
Moraes-Fontes et al. de novo Fatal CTLA-4 heterozygosity
